Arnon Rosenthal Sells 87,216 Shares of Alector (NASDAQ:ALEC) Stock

Posted by Geri Gentry on Jun 5th, 2026

Alector, Inc. (NASDAQ:ALEC – Get Free Report) CEO Arnon Rosenthal sold 87,216 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the transaction, the chief executive officer directly owned 2,367,206 shares in the company, valued at $4,663,395.82. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Alector Trading Up 2.0%

ALEC opened at $1.81 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.25 and a quick ratio of 5.25. The company’s 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $1.94. Alector, Inc. has a 1-year low of $1.09 and a 1-year high of $3.40. The firm has a market capitalization of $200.96 million, a price-to-earnings ratio of -1.52 and a beta of 0.61.

Alector (NASDAQ:ALEC – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $9.67 million. Analysts expect that Alector, Inc. will post -0.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on ALEC shares. Morgan Stanley reissued an “underweight” rating and issued a $2.00 target price on shares of Alector in a research note on Monday, May 4th. Cantor Fitzgerald raised shares of Alector from a “neutral” rating to an “overweight” rating in a research note on Wednesday, April 15th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BTIG Research raised shares of Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alector in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.63.

Read Our Latest Stock Report on Alector

Hedge Funds Weigh In On Alector

Institutional investors have recently modified their holdings of the business. Lexington Partners L.P. acquired a new position in shares of Alector in the third quarter worth $30,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Alector in the fourth quarter worth $30,000. Prudential Financial Inc. acquired a new position in shares of Alector in the second quarter worth $30,000. Hershey Trust Co. grew its stake in shares of Alector by 100.0% in the fourth quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after acquiring an additional 10,286 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Alector in the fourth quarter worth $34,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Company Profile

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.